ReviewRSC advances2026
Trends towards multidrug-resistant bacteria: heterocyclic compounds containing antimicrobial agents: review.
Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid emergence of multidrug-resistant (MDR) pathogens poses a severe global health threat, as current antibiotics become increasingly ineffective due to antimicrobial resistance (AMR), irrational drug use across human, veterinary, and agricultural sectors, and aggressive pharmaceutical marketing. This crisis is further aggravated by a shortage of novel antibacterial agents entering clinical practice, highlighting the urgent need for new treatment modalities and drug repurposing strategies. In response, heterocyclic compounds have emerged as a highly versatile and promising class of organic molecules with unique broad-spectrum antibacterial activity against both Gram-positive and Gram-negative strains. To successfully translate these bench discoveries into clinical solutions against superbugs, a combined approach integrating rigorous antibiotic stewardship principles with streamlined regulatory pathways is essential.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.